PCRX Pacira BioSciences, Inc.

NEUTRAL Impact: 2/10 144
Horizon immediate Filed Jun 4, 2026 Processed 8d 19h ago SEC 0001959173-26-004324
Form 144 — notice of proposed sale of securities
Latest settled — T+1d ⚠ clustered
PCRX ▲ +0.35% at T+1d
NEUTRAL call ✓ call won +0.35% · α vs SPY +2.95% · entry $22.67 → $22.75
Next anchor: T+5d due yesterday
Currently $22.99 · +1.41% from $22.67 entry
Entry anchored
Jun 4, 09:48 AM ET
via Databento tick
T+1d
+0.35%
call +0.35% · α +2.95%
$22.75
settled 8d ago
T+5d
call — · α —
due yesterday
T+20d
call — · α —
in 20d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Kristen Williams, an officer of Pacira BioSciences, filed a Form 144 intent to sell 10,259 shares of common stock, valued at approximately $228,468 based on a June 4, 2026 market price of $22.28. The shares were acquired through restricted stock vesting on June 3, 2026, as compensation. The sale is a routine post-vesting monetization by an officer, representing a small fraction of the company's $878M market cap, and does not signal material insider concern.

Actionable Insight

Form 144 signals intent to sell, not a completed transaction. The small dollar amount relative to market cap and routine nature (post-RSU vesting) make this a neutral event. No immediate trading signal; monitor for any follow-on Form 4 filings to confirm execution.

Key Facts

  • Officer Kristen Williams filed Form 144 to sell 10,259 shares of PCRX common stock
  • Proceeds estimated at ~$228,468 based on filing date price (~$22.28/share)
  • Shares acquired via restricted stock vesting on June 3, 2026 (compensation)
  • Sale executed through Fidelity Brokerage Services LLC
  • Company market cap ~$878M; proposed sale ~0.026% of outstanding shares
  • Reporting owner is an officer of Pacira BioSciences

Financial Impact

Proposed sale of ~$228K in shares, ~0.026% of market cap — immaterial

dilution

Risk Factors

  • Insider could still execute the sale, but magnitude is too small to affect stock
  • No material negative signal from an officer selling RSU shares for cash

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-004324
Document: 0001959173-26-004324-index.html0001959173-26-004324
Document: 0001959173-26-004324.txt0001959173-26-004324
13 reports for PCRX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PCRX — sortable, filterable
Type Now
Jun 13, 2026
today
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+1
Jun 4, 2026
8d ago
DEFA14A
MIXED ★ 6/10
$22.67 awaiting T+1awaiting T+1$22.99 (+1.41%)
Jun 4, 2026
8d ago
144
NEUTRAL ★ 2/10
$22.67 $22.75▲ +0.35%▲ +2.95%$22.99 (+1.41%)
Jun 1, 2026
11d ago
DEFA14A
NEUTRAL ★ 5/10
$22.25 $22.32▲ +0.31%▲ +1.04%$22.99 (+3.33%)
May 27, 2026
16d ago
DEFA14A
MIXED ★ 5/10
$23.68 $23.22▼ −1.94%▼ −2.18%$22.99 (−2.91%)
May 26, 2026
17d ago
DEFA14A
MIXED ★ 6/10
$24.04 $23.68▼ −1.50%▼ −2.05%$22.99 (−4.37%)
May 20, 2026
23d ago
DEFA14A
MIXED ★ 6/10
$23.48 $23.35▼ −0.55%▼ −1.00%$22.99 (−2.09%)
May 20, 2026
23d ago
Press Release
MIXED ★ 7/10
$23.00 $23.48▲ +2.09%▲ +1.89%$22.99 (−0.04%)
Apr 30, 2026
6w ago
8-K
NEUTRAL ★ 4/10
$24.44 $24.69▲ +1.02%▲ +1.36%$22.99 (−5.93%)
Apr 17, 2026
8w ago
PREC14A
MIXED ★ 6/10
$24.90 $24.64▼ −1.04%▼ −0.39%$22.99 (−7.67%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (52h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access